龙虎榜数据显示，该股因连续三个交易日内，涨幅偏离值累计达20%上榜龙虎榜1次，买卖居前营业部 中，机构净买入1640.42万元，营业部席位合计净卖出799.64万元。 4月25日公司发布的一季报数据显示，一季度公司共实现营业总收入3.70亿元，同比增长1.37%，实现净 利润0.55亿元，同比下降6.56%。7月15日公司公布了上半年业绩预告，预计实现净利润3.30亿元至3.55 亿元，同比变动区间为222.42%~246.85%。（数据宝） 近日该股表现 力生制药盘中涨停，已连收3个涨停板，截至9:32，该股报26.27元，换手率7.22%，成交量1807.18万 股，成交金额4.68亿元，涨停板封单金额为1.06亿元。连续涨停期间，该股累计上涨33.08%，累计换手 率为25.85%。最新A股总市值达67.70亿元，A股流通市值65.76亿元。 证券时报·数据宝统计，两融数据来看，该股最新（7月16日）两融余额为1.97亿元，其中，融资余额 1.97亿元，较前一个交易日增加930.23万元，环比增长4.94%，近3日累计减少1641.41万元，环比下降 7.68%。 | 日期 | 当日涨跌幅（%） | 换 ...

证券研究报告 东吴证券晨会纪要 东吴证券晨会纪要 2025-07-17 宏观策略 [Table_MacroStrategy] 宏观点评 20250715：城市更新的空间有多大？——2025 年 7 月中央城市 工作会议点评 城市更新"预计能够落地多大规模？"十五五"期间，城市更新预计至少 能够完成 4.48 万亿元总投资，折合每年近 9000 亿元。未来，城市更新的 潜在需求预计将主要来自城中村改造、老旧小区改造与城市基础设施建 设改造。其中： （1）老旧小区改造与城市基础设施建设改造：2024 年， 国家发改委披露"2023-2024 年安排中央预算内投资、增发国债和超长期 特别国债资金超过 4700 亿，重点支持地下管网改造、城镇老旧小区改造 等城市更新项目。今后几年，城市更新仍是政府投资的支持重点。"如果 未来保持这样的投资强度，那么在"十五五"期间,即使不考虑财政资金 的撬动作用，老旧小区改造与城市基础设施建设改造预计至少也可贡献 2.35 万亿元新增投资。 （2）城中村改造：2020 年，全国城镇家庭居住 的自建房总建筑面积估算值约为 6.66 亿平方米。剔除 2025 年底之前可 能已完成改造部分 ...

Group 1: Macro Insights - The 2025 Central Urban Work Conference emphasized the need for high-quality urban development, transitioning from rapid growth to stable development, focusing on improving existing urban infrastructure rather than large-scale expansion [6][7][9] - The conference highlighted the importance of a people-centered approach, aiming for sustainable urban development that meets the needs of citizens while enhancing urban governance and service levels [6][9] Group 2: Non-Bank Financial Sector - The introduction of supporting rules for the Sci-Tech Innovation Board (STAR Market) aims to enhance the predictability of IPO processes for tech companies, thereby supporting high-level development in the technology sector [10] - Brokerage firms are expected to report significant profit increases for the first half of the year, driven by growth in wealth management and proprietary investment businesses, with some firms seeing net profit growth exceeding 100% [10] Group 3: Chemical Pharmaceutical Industry - The PDE3/4 inhibitors for COPD treatment are showing rapid sales growth, with the first product, Ensifentrine, expected to generate significant revenue in the coming years, indicating a strong market potential for innovative therapies [12][14][15] - Clinical trials for PDE3/4 inhibitors are progressing well, with positive results in improving lung function and reducing exacerbation rates in COPD patients [14][15] Group 4: Retail and Consumer Goods - In June 2025, China's retail sales grew by 4.8% year-on-year, which was below market expectations, indicating a slowdown in consumer spending, particularly in discretionary categories [16][17] - The performance of online retail channels outpaced traditional retail, with significant growth in categories such as food and clothing, suggesting a shift in consumer purchasing behavior [16][17] Group 5: Renewable Energy and UCO Market - The sustainable aviation fuel (SAF) market is expected to see significant growth, with EU regulations mandating increasing SAF blending ratios, which will drive demand for used cooking oil (UCO) as a feedstock [20][21] - The domestic market for SAF is also gaining momentum, with pilot projects and supportive policies being implemented, indicating a favorable environment for UCO suppliers [20][21] Group 6: Photovoltaic Industry - Prices for polysilicon, silicon wafers, and battery cells have seen substantial increases, driven by strong demand and active market conditions, suggesting a bullish outlook for the photovoltaic supply chain [22][24] - The market for photovoltaic components is expected to experience price adjustments due to rising costs in upstream materials, while demand remains stable [24]

Group 1: Short Drama Industry - The short drama gaming sector is experiencing increased popularity, with companies like Tiandi Online and Hengdian Film achieving significant stock gains [1] - DataEye reports that by the first half of 2025, micro-short drama users will reach 696 million, with a half-year increase of 34 million, and average daily viewing time at 101 minutes [1] - The National Radio and Television Administration is promoting the quality and standardization of micro-short dramas while encouraging cross-industry integration [1][2] Group 2: Pharmaceutical Industry - Pharmaceutical stocks are seeing significant gains, with companies like Lizhu Group and Hasi Lian reaching their daily price limits [2] - The National Medical Products Administration has announced the selection of 55 products for the 11th batch of centralized procurement, focusing on maintaining clinical stability and quality [2] - Analysts believe that the rise of innovative drugs is sustainable, with a projected market size of 50.4 billion yuan in 2024, a 35% increase year-on-year [3] Group 3: Nuclear Fusion Industry - The 2025 China International Nuclear Energy and Nuclear Fusion Industry Conference is being held in Shanghai, showcasing innovations across the nuclear fusion technology spectrum [3][4] - The number of members in China's controllable nuclear fusion innovation consortium is expected to increase significantly by the end of 2024, with active financing in commercial nuclear fusion enterprises [4] - Approximately 70% of commercial fusion companies anticipate achieving their first commercial demonstration pile by 2035 [4] Group 4: Intellectual Property - The Ministry of Public Security has issued guidelines to combat intellectual property crimes, emphasizing the protection of technological innovation [5] - The Chinese intellectual property service market is projected to reach 285 billion yuan in 2023, with expectations of continued high growth [5] Group 5: eSIM Technology - China Unicom has launched eSIM mobile services, marking a significant step towards commercial trials of this technology [6][7] - The demand for eSIM is expected to grow due to the rise of AI models and the increasing number of IoT connections [7] Group 6: Environmental Protection - The Ministry of Water Resources is implementing strategies for comprehensive river protection and governance, focusing on water resource conservation and ecological protection [8] Group 7: Macro and Industry News - The State Council is focusing on policies to strengthen domestic circulation and regulate the competition in the new energy vehicle industry [9][10] - The National Energy Administration reported a record national power load exceeding 1.5 billion kilowatts [12]

以下文章来源于估值之家 ，作者估值之家 估值之家 . 推动投资者认知进步...... 导 语： 令人疑惑的是，无论券商或基金，似乎对永安药业的兴趣都不太大。 2025年7月15日，永安药业(002365.SZ)股价大幅低开，盘中多次触及跌停，又反复打开跌停板，但最终收盘封死跌停。过去七个交易日 时间，永安药业股价最大回撤已经来到-28.04%。 | W | 永安药业(002365) | | | | --- | --- | --- | --- | | | 闭市 07-15 15:00:00 | | | | 23.05 | 额 10.75亿 股本 2.95亿 市盈 237 | 力得 | | | -2.56 -10.00% 换 18.80% 市值1 68亿 | 市净 3.49 | 품 ■ | | | 分时 | те 周K 月K | 更多 () | | | 盟加 | 均价:23.29 盘口 资金 | | | | 28.17 | 10.00% 卖五 23.09 | | 37 | | | 포 | 23.08 | 30 | | | 英三 | 23.07 | dd | | | 集二 | 23.06 | 429 | | 25. ...

Group 1 - China's Ministry of Commerce issued a notice to encourage foreign investors to increase their investments in China through a tax credit policy for profit reinvestment, highlighting the importance of tax incentives in stabilizing investment expectations and reducing costs [2] - The National Energy Administration reported that the national maximum electricity load reached a record high of 1.506 billion kilowatts, an increase of 0.055 billion kilowatts compared to the previous year, indicating a critical period for energy supply during the summer peak [3] - Seven major potassium fertilizer distribution companies in China jointly announced an initiative to increase potassium fertilizer supply and reduce prices, aiming to stabilize market expectations and return prices to reasonable levels [4] Group 2 - The Ministry of Industry and Information Technology released a new product announcement list that includes Tesla's six-seat Model Y L [5] - Postal Savings Bank plans to invest 10 billion yuan to establish China Post Financial Asset Investment Co., Ltd [5] - Jinggong Steel Structure signed a contract for a 550 million yuan project in Jeddah, Saudi Arabia, which will be used for the FIFA World Cup events [5] Group 3 - Shanghai Material Trade Company experienced a four-day stock price increase, stating that there have been no significant changes in its fundamentals [6] - Guangsheng Tang's GST-HG131 has been included in the list of breakthrough therapy designations by the drug review center, although this does not guarantee market approval [6] - Medike's plan to acquire 100% of Haisholi and INNOWAVE VIETNAM for 2 billion Korean won will allow the company to directly enter the Samsung supply chain [6] Group 4 - Anker Innovations is researching matters related to issuing shares overseas [7] - Shantui Co., Ltd. plans to issue H-shares and apply for listing on the main board of the Hong Kong Stock Exchange [7] - ASML, a Dutch lithography machine giant, stated that U.S. tariff policies have created uncertainty regarding the company's growth prospects [8]

Market Overview - On July 16, the A-share market saw a total of 69 stocks hit the daily limit, with 55 stocks remaining after excluding 13 ST stocks and 1 delisted stock, resulting in a limit-up rate of 74.19% [1] Top Gainers - Shuangwei New Materials achieved the highest limit-up with a closing price of 23.24 yuan per share and a limit-up order volume of 361,600 hands, marking its sixth consecutive limit-up [2] - Other notable limit-up stocks include Farsen, Yingli Automotive, and Huangshi Group, with limit-up order volumes of 222,900 hands, 210,100 hands, and 208,000 hands respectively [2] Performance Forecasts - Zhongdian Port announced a half-year performance forecast, expecting a net profit attributable to shareholders of 170 million to 190 million yuan, representing a year-on-year growth of 55.06% to 73.3% [3] - Weichai Heavy Industry anticipates a net profit of 132 million to 151 million yuan for the first half of the year, reflecting a year-on-year increase of 40% to 60% [7] - Dayilong expects a net profit of 75 million to 100 million yuan, indicating a significant year-on-year growth of 162.38% to 249.84% [8] - Tianchen Co. forecasts a net profit of 18.8 million to 22.5 million yuan, with an impressive year-on-year growth of 640% to 786% [9] Industry Trends - The semiconductor industry is experiencing a structural recovery, driven by the rapid iteration of artificial intelligence technology, which has increased demand for processors and related electronic components [3] - Companies like Zhejiang Rongtai and Donggang Co. are actively expanding their business in the robotics sector, with significant collaborations and product developments underway [10] Investment Activity - Institutional investors showed strong interest in Huahong Technology, with net purchases exceeding 100 million yuan [11] - The top three net purchases by institutional seats included Huahong Technology, Seli Medical, and Beifang Long, with amounts of 113 million yuan, 7.426 million yuan, and 7.048 million yuan respectively [12]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The report highlights the acquisition of 95.09% of Shanghai Lixin Pharmaceutical for approximately $500 million, accelerating the company's globalization efforts [5][7] - The innovative pipeline of Lixin, including dual antibodies and ADCs, is expected to significantly enhance the company's core competitiveness in the oncology field [7] - The financial forecasts indicate a strong growth trajectory for revenue and net profit, with expected net profits of RMB 4.639 billion, RMB 5.003 billion, and RMB 5.405 billion for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 32.56%, 7.84%, and 8.05% [6][8] Financial Summary - Revenue projections for the company are as follows: RMB 26,199 million in 2023, RMB 28,866 million in 2024, RMB 32,562 million in 2025, RMB 36,315 million in 2026, and RMB 40,723 million in 2027, with corresponding growth rates of -8.97%, 10.18%, 12.80%, 11.53%, and 12.14% [6][8] - The projected earnings per share (EPS) are RMB 0.13 for 2023, RMB 0.19 for 2024, RMB 0.25 for 2025, RMB 0.27 for 2026, and RMB 0.29 for 2027 [6][8] - The company’s return on equity (ROE) is expected to be 7.7% in 2023, increasing to 12.7% in 2025, and then slightly decreasing to 11.5% by 2027 [6][8]

总而言之，就是大家别再忧心大盘会调到什么位置，调下来看你的这个票是不是机会就行了，也别呢太 激动的就去追那些券商，多元金融啊呃没有呈现板块行情，他们一呈现板块行情，那不又重现去年924 的那波走法吗？那样的走法的话显然是不太符合市场的节奏的，因为你看924就涨到国庆节前，然后后 面就是长期的这种震荡，显然是不太合适的，所以震荡的这种慢牛爬升调一调，比如下半个月把3500点 夯实，震荡之后，然后后面慢慢走高，这就是比较明朗的。 第二个方面就是资金，昨天大家看到央行提前发布预告，15号进行了14,000亿的买断式逆回购，同时当 天进行了7天逆回购的补充流动性，今天继续补充流动性。这个时间点如果朋友们说只是税息，那实际 上这个时候市场的资金面上利率水平并没有显示出稍微高起来的一个状态，只是大盘好像要调的意思， 资金就给了，有了资金那你说大盘往下跌跌哪去，所以看懂这点就行了。 第三一点就是现在这个时候的策略，这个怎么办？就调下来，个股调下来板块有机会的该抓就抓就行 了。哪几个方向？第一个从长期而言还是继续要抓好大家高股息的大央企，比如说类似三桶油三大运营 商等这些，还是要做长期的这样一个跟踪布局。第二一个就是各大行业 ...

证券之星刘凤茹 今年以来不断推出的利好政策点燃了创新药热度，广生堂（300436）(300436.SZ)在二级市场受资金追 捧，7月16日其股价创下77.09元/股的阶段性新高。广生堂股价与业绩"冰火两重天"，其归母净利润已现 四连亏(2021-2024年)。 证券之星注意到，深陷业绩泥潭的广生堂，今年抛出一份9.77亿元的定增募资计划，其中超六成押注两 款乙肝创新药研发。不过，控股子公司广生中霖(乙肝创新药实施主体)2023年增资附加回购条款，是否 构成"明股实债"、前次募投项目"烂尾"遭遇监管拷问。近期，广生堂在回复函中坚称"无明股实债"，拟 借国谈政策红利破局。 创新药研发占六成 根据广生堂披露的2025年定增方案来看，创新药研发项目是广生堂此次募资后投入的大头，拟使用募集 资金5.98亿元用于创新药研发项目，该项目投资金额为6.31亿元。将募集资金8849.05万元用于中药传统 名方产业化项目，该项目投资金额为1.05亿元；拟使用募集资金2.9亿元用于补充流动资金。 | 项目名称 | 投资金额 | 拟使用募集资金 | 募集资金是否属 | | --- | --- | --- | --- | | | | ...